References of "Jerusalem, Guy"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailA phase 1b study of Trebananib plus Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in patients with HER2+ locally recurrent or metastatic breast cancer
Kaufman, P.A.; Freyer, G.; Kemeny, M. et al

in Cancer Research (2015, May), 75(9), 5-19-14

Detailed reference viewed: 28 (0 ULg)
Full Text
Peer Reviewed
See detailBRCA1 germline mutation and glioblastoma development: report of cases
Boukerroucha, Meriem ULg; Josse, Claire ULg; SEGERS, Karin ULg et al

in BMC Cancer (2015), 15

Background Germline mutations in breast cancer susceptibility gene 1 (BRCA1) increase the risk of breast and ovarian cancers. However, no association between BRCA1 germline mutation and glioblastoma ... [more ▼]

Background Germline mutations in breast cancer susceptibility gene 1 (BRCA1) increase the risk of breast and ovarian cancers. However, no association between BRCA1 germline mutation and glioblastoma malignancy has ever been highlighted. Here we report two cases of BRCA1 mutated patients who developed a glioblastoma (GBM). Cases presentation Two patients diagnosed with triple negative breast cancer (TNBC) were screened for BRCA1 germline mutation. They both carried a pathogenic mutation introducing a premature STOP codon in the exon 11 of the BRCA1 gene. Few years later, both patients developed a glioblastoma and a second breast cancer. In an attempt to clarify the role played by a mutated BRCA1 allele in the GBM development, we investigated the BRCA1 mRNA and protein expression in breast and glioblastoma tumours for both patients. The promoter methylation status of this gene was also tested by methylation specific PCR as BRCA1 expression is also known to be lost by this mechanism in some sporadic breast cancers. Conclusion Our data show that BRCA1 expression is maintained in glioblastoma at the protein and the mRNA levels, suggesting that loss of heterozygosity (LOH) did not occur in these cases. The protein expression is tenfold higher in the glioblastoma of patient 1 than in her first breast carcinoma, and twice higher in patient 2. In agreement with the high protein expression level in the GBM, BRCA1 promoter methylation was not observed in these tumours. In these two cases, despite of a BRCA1 pathogenic germline mutation, the tumour-suppressor protein expression is maintained in GBM, suggesting that the BRCA1 mutation is not instrumental for the GBM development. [less ▲]

Detailed reference viewed: 43 (8 ULg)
Full Text
Peer Reviewed
See detailMetabolomic, proteomic and preclinical imaging of patient-derived tumor xenografts for improving treatment of liver metastases patients
Perez Palacios, A; Blomme, A; Boutry, S et al

in Acta Gastro-Enterologica Belgica (2015, March), 78(1), 134

Detailed reference viewed: 61 (17 ULg)
See detailClinical significance of MT4-MMP and EGFR expression in Breast Cancer
Yip, Cassandre ULg; PAYE, Alexandra ULg; Truong, Alice ULg et al

Scientific conference (2015, February 11)

Detailed reference viewed: 22 (7 ULg)
Full Text
Peer Reviewed
See detailOncological and surgical outcome after oncoplastic breast surgery
NIZET, Jean-Luc ULg; MAWEJA, Sylvie ULg; LAKOSI, Ferenc ULg et al

in Acta Chirurgica Belgica (2015), 115

BACKGROUND: Oncoplastic surgery combines breast-conserving treatment and plastic surgery techniques. The aim of the study was to identify breast and tumor-related characteristics that contribute to the ... [more ▼]

BACKGROUND: Oncoplastic surgery combines breast-conserving treatment and plastic surgery techniques. The aim of the study was to identify breast and tumor-related characteristics that contribute to the rate of complications and recurrence. METHODS: This retrospective study included 72 patients with a median follow-up of 32 months. For each patient, a comprehensive set of data was collected, including epidemiology, tumor characteristics, preoperative information, detailed pathology reports, radiotherapy treatment and type of surgical technique. The rate of complications, recurrence and survival were studied. RESULTS: Complete tumor removal was performed with clear margins in all patients but in 25 of them margins were less than 2 mm. One patient had local recurrence and another developed distant metastases. The study showed that the size of the margin was not predictive of recurrence as long as not positive; the greater the resection volume, the larger the excision margin. The resection size was the only factor influencing complications and no specific tumor-related factor significantly increased the complication rate. Surgical complications did not delay the initiation of chemotherapy and radiotherapy. CONCLUSIONS: This is the first oncoplastic study where both tumor and breast characteristics were analyzed using the most recent criteria of the literature. Oncoplastic surgery can be considered as oncologically safe. The resection size was the sole significant risk factor for postoperative complications. Complications after oncoplastic breast surgery did not differ neoadjuvant therapy. Long-term event-free survival was excellent (96% at 7 years). [less ▲]

Detailed reference viewed: 47 (18 ULg)
See detailClinical significance of MT4-MMP and EGFR expression in Breast Cancer
Yip, Cassandre ULg; PAYE, Alexandra ULg; Truong, Alice ULg et al

Scientific conference (2015, January 31)

Detailed reference viewed: 19 (7 ULg)
Full Text
Peer Reviewed
See detailMesenchymal stem cells shed amphiregulin at the surface of lung carcinoma cells in a juxtacrine manner .
Carnet, Oriane ULg; Lecomte, Julie ULg; Masset, Anne et al

in Neoplasia : An International Journal for Oncology Research (2015), 17(7), 552-63

Solid tumors comprise cancer cells and different supportive stromal cells, including mesenchymal stem cells (MSCs), which have recently been shown to enhance tumor growth and metastasis. We provide new ... [more ▼]

Solid tumors comprise cancer cells and different supportive stromal cells, including mesenchymal stem cells (MSCs), which have recently been shown to enhance tumor growth and metastasis. We provide new mechanistic insights into how bone marrow (BM)-derived MSCs co-injected with Lewis lung carcinoma cells promote tumor growth and metastasis in mice. The proinvasive effect of BM-MSCs exerted on tumor cells relies on an unprecedented juxtacrine action of BM-MSC, leading to the trans-shedding of amphiregulin (AREG) from the tumor cell membrane by tumor necrosis factor-α-converting enzyme carried by the BM-MSC plasma membrane. The released soluble AREG activates cancer cells and promotes their invasiveness. This novel concept is supported by the exploitation of different 2D and 3D culture systems and by pharmacological approaches using a tumor necrosis factor-α-converting enzyme inhibitor and AREG-blocking antibodies. Altogether, we here assign a new function to BM-MSC in tumor progression and establish an uncovered link between AREG and BM-MSC. [less ▲]

Detailed reference viewed: 112 (26 ULg)
Full Text
Peer Reviewed
See detailEvaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers.
Boukerroucha, Meriem ULg; Josse, Claire ULg; El Guendi, Sonia ULg et al

in BMC cancer (2015), 15(1), 755

BACKGROUND: The BRCA1 gene plays a key role in triple negative breast cancers (TNBCs), in which its expression can be lost by multiple mechanisms: germinal mutation followed by deletion of the second ... [more ▼]

BACKGROUND: The BRCA1 gene plays a key role in triple negative breast cancers (TNBCs), in which its expression can be lost by multiple mechanisms: germinal mutation followed by deletion of the second allele; negative regulation by promoter methylation; or miRNA-mediated silencing. This study aimed to establish a correlation among the BRCA1-related molecular parameters, tumor characteristics and clinical follow-up of patients to find new prognostic factors. METHODS: BRCA1 protein and mRNA expression was quantified in situ in the TNBCs of 69 patients. BRCA1 promoter methylation status was checked, as well as cytokeratin 5/6 expression. Maintenance of expressed BRCA1 protein interaction with BARD1 was quantified, as a marker of BRCA1 functionality, and the tumor expression profiles of 27 microRNAs were determined. RESULTS: miR-548c-5p was emphasized as a new independent prognostic factor in TNBC. A combination of the tumoral expression of miR-548c and three other known prognostic parameters (tumor size, lymph node invasion and CK 5/6 expression status) allowed for relapse prediction by logistic regression with an area under the curve (AUC) = 0.96. BRCA1 mRNA and protein in situ expression, as well as the amount of BRCA1 ligated to BARD1 in the tumor, lacked any associations with patient outcomes, likely due to high intratumoral heterogeneity, and thus could not be used for clinical purposes. CONCLUSIONS: In situ BRCA1-related expression parameters could be used for clinical purposes at the time of diagnosis. In contrast, miR-548c-5p showed a promising potential as a prognostic factor in TNBC. [less ▲]

Detailed reference viewed: 46 (11 ULg)
Full Text
Peer Reviewed
See detailBIOPSIE DES LESIONS SUSPECTES CHEZ LES PATIENTS AYANT PRESENTE UN CANCER DU SEIN.
Colin, P.-E.; Schroeder, H.; Gonne, E. et al

in Revue medicale de Liege (2015), 70(11), 563-8

Discordances between hormone receptors and HER2 status in primary and metastatic breast cancer have been reported by several studies. In this context, systematic biopsies could be clinically relevant in ... [more ▼]

Discordances between hormone receptors and HER2 status in primary and metastatic breast cancer have been reported by several studies. In this context, systematic biopsies could be clinically relevant in breast cancer to confirm the biological characteristics of a suspicious lesion. In this article, illustrated by 2 case reports and based on a recent review on this topic, we discuss the clinical significance of receptor discordances and possible diagnosis of a secondary primary tumor. The role of these biopsies for the identification of new therapeutic targets is also envisaged as well as underlying mechanisms for receptors' modification like tumoral heterogeneity, clonal selection and technical artifacts. [less ▲]

Detailed reference viewed: 93 (2 ULg)
Full Text
Peer Reviewed
See detailPredictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer : combined exploratory analysis from BOLERO-1 and BOLERO-3
Slamon, Dennis; Hurvitz, Sara; Chen, David et al

in Journal of Clinical Oncology (2015), 33(suppl ; abstr 512),

Detailed reference viewed: 45 (1 ULg)
Full Text
Peer Reviewed
See detailImplementation of geriatric assessment - based recommendations in older patients with cancer : a multicenter prospective study
Baitar, A; Kenis, C; Moor, R et al

in Journal of Geriatric Oncology (2015), 6

Detailed reference viewed: 19 (2 ULg)
Full Text
Peer Reviewed
See detailEffect of itraconazole and rifampin on the pharmacokinetics of olaparib table formulation in patients with advanced solid tumors : phase I open-label studies
Plummer, Elizabeth R.; Verheul, Henk M.W.; Rottey, Sylvie et al

in Journal of Clinical Oncology (2015), 33(suppl : abstr 2565),

Detailed reference viewed: 26 (3 ULg)
Full Text
Peer Reviewed
See detailRelationship of germline polymorphisms to docetaxel toxicity in the ROSE/TRIO-012 trial
Damaraju, Sambasivarao; Gorbunova, Vera; Gelmon, Karen A. et al

in Journal of Clinical Oncology (2015), (suppl abstr 540),

Detailed reference viewed: 21 (1 ULg)
Full Text
Peer Reviewed
See detailA nationwide implementation of a multidisciplinary geriatric assessment and intervention program in belgian older patients with cancer
Kenis, C; Flamaing, J; Debruyne, P.R. et al

in Journal of Geriatric Oncology (2015), 6(S13-S27), 001

Detailed reference viewed: 29 (1 ULg)
Full Text
Peer Reviewed
See detailAvelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors : assessment of safety and tolerability in a phase I, open-label expansion study
Kelly, Karen; Patel, Manish R.; Infante, Jeffrey R. et al

in Journal of Clinical Oncology (2015), 33(suppl ; abstr 3044),

Detailed reference viewed: 94 (0 ULg)